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Introduction
Paediatric rheumatic diseases (PRD) form a group of (rare)
diseases that can lead to significant morbidity. Evidence-
based guidelines are sparse and treatment regimens differ
throughout Europe. In 2012, a European initiative called
SHARE (Single Hub and Access point for pediatric
Rheumatology in Europe) was granted by the European
Agency for Health and Consumers (project number 2011
1202) to optimize and disseminate diagnostic and manage-
ment regimens in Europe for children with PRD.
Objectives
Workpackage 5 (WP5) aims to develop best practices of
diagnosis and treatment for PRD.
Methods
Evidence based recommendations were developed using
the European League Against Rheumatism (EULAR) stan-
dard operating procedure [1]: Expert committees were
formed, consisting of paediatric rheumatologists and
experts in the 4 core PRD: Juvenile Idiopathic arthritis
(JIA), Juvenile Dermatomyositis (JDM), Systemic Lupus
Erythematosus (SLE, including antiphospholipid syndrome
and vasculitis) and Juvenile Scleroderma (JSc, localized
and systemic). The periodic fevers were incorporated in a
later phase of the project and will be discussed separately.
The expert committees defined domains and search terms
for systematic literature reviews, which were executed in
July 2013 in Medline, Embase and Cochrane databases.
Subsequently, all available abstracts were checked for
inclusion (published after 1970, English, no case reports,
case series only when including at least 3 pediatric
patients). All relevant papers were subsequently scored for
validity and level of evidence (LOE) by 2 independent
experts. In case of disagreement, a 3rd independent expert
confirmed the validity and LOE. Papers and scores were
used to develop recommendations that were evaluated by
all experts via an online survey as a 1st step. Those with
< 80% agreement in the survey were reformulated. Finally,
recommendations were discussed at a consensus meeting
with all experts present, using the nominal group
technique [2]. Recommendations were accepted if > 80%
agreement was reached.
Results
Table 1 shows the number of scored papers after the
standardised literature search and the number of recom-
mendations on diagnosis and treatment for each PRD.
Conclusion
Based upon standardised literature searches, WP5 of
SHARE developed evidence based recommendations for
diagnosis and treatment of PRD. These recommendations
were discussed and agreed upon in a 1st consensus
meeting and will serve as input for the ultimate goal:
development of best practices for care and management of
PRD throughout Europe. These best practices will be
finalized in a 2nd consensus meeting in March 2015
and presented to all stakeholders including paediatric
rheumatology units throughout Europe, patient/parent
organisations and health authorities.
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